- Conditions
- Prostate Adenocarcinoma
- Interventions
- Flibanserin 100 MG, Placebo, Androgen deprivation therapy
- Drug
- Lead sponsor
- Andrew McDonald
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
- Drug · Other · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Zin W Myint
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Salt Lake City, Utah
- Conditions
- Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- Interventions
- Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT)
- Drug · Other · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Cleveland, Ohio • Madison, Wisconsin
- Conditions
- Metastatic Castration Sensitive Prostate Cancer
- Interventions
- Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer, Cancer of the Prostate
- Interventions
- Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
- Device · Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
- Interventions
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 20
- States / cities
- Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide, Physician choice Androgen Deprivation (Hormone) Therapy
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- Radiation, MRI, Androgen Deprivation Therapy
- Radiation · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois